I was looking over some clinical trials and came across this "Lipitor and Celebrex" 2017 trial.
ncbi.nlm.nih.gov/pmc/articl...
So, it looks like a statin (I think a water based one) plus NSAID (Celebrex) may slow down PC.
But, Celebrex seems to be associated with higher heart problems-
If one is on Lupron/Zytiga, like myself, heart problems are a concern.
A fatal heart attack would really slow down prostate cancer.
Your thoughts?
Craig
Craig,
Not a human study.
See my posts of 2 years ago:
"Non-PCa Prescription Drugs: Statins"
healthunlocked.com/advanced...
& "Non-PCa Prescription Drugs: Statins - Lipophilic or Hydrophilic?"
healthunlocked.com/advanced...
& "Non-PCa Prescription Drugs: Celebrex"
healthunlocked.com/advanced...
-Patrick
That was a lab/mouse study, not a clinical trial. Unfortunately, what works in mice usually does not work in humans. Celebrex (without Zometa) has been proven to NOT benefit men with prostate cancer in two major prospective clinical trials. I have not seen anything about adverse events from interaction with hormone therapy.
I saw that the VA did a historical study of over 80,000 vets who had prostate cancer. Those on ADT and statins had a much better survival rate. Dr. Myers used to prescribe statins for those of us on ADT who were not on statins. I was on lipitor before I started ADT and have done well. Human study of one.
The much-maligned mouse model is nevertheless still making contributions to the advancement of science.
"Using the mouse to model human disease: increasing validity and reproducibility
Monica J. Justice1,* and Paraminder Dhillon2"
Dear Bill:
It is online under Effect of statins on patients with ADT. It is an NCIB file. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
Anderson-Carter I1, Posielski N1, Liou JI2, Khemees TA1, Downs TM1, Abel EJ1, Jarrard DF1, Richards KA3.
Author information
Abstract
BACKGROUND:
Statins are thought to possess antineoplastic properties related to their effect on cell proliferation and steroidogenesis. Progression to castrate resistant prostate cancer (CaP) includes de-regulation of androgen synthesis suggesting a role for statins in this setting. Our goal was to assess the role of statin use on oncologic outcomes in patients with advanced CaP being treated with androgen deprivation therapy (ADT).
METHODS:
The national VA database was used to identify all men diagnosed with CaP who were treated with ADT for at least 6 months between 2000 and 2008 with follow-up through May 2016. Our cohort was stratified based on statin use of at least 6 months duration during the same time. Multivariable Cox proportional hazards analyses with inverse propensity score weighted (IPSW) adjustment were calculated to assess for primary outcomes of CaP-specific survival (CSS), overall survival (OS) and skeletal related events (SREs).
RESULTS:
A total of 87,346 patients on ADT were included in the study cohort, 53,360 patients used statins and 33,986 did not. Statin users were younger in age (median 73 vs. 76, P < 0.001), more likely to have a higher Charlson comorbidity index (CCI) >3 (3.1% vs. 2.5%, P < 0.001) and more likely to have a high grade (Gleason score 8-10) cancer (12.3% vs. 10.9%, P < 0.001). Statin users had longer OS (median 6.5 vs. 4.0 years P < 0.001) and decreased death from CaP (5-year CSS 94.0% vs. 87.3%, P < 0.001). Statin use was also associated with longer time to a SRE (median 5.9 vs. 3.7 years, P < 0.001). On multivariable Cox proportional hazards analysis with inverse propensity score weighted, statin use was an independent predictor of improved OS (hazard ratio [HR] 0.66, confidence interval [CI] 0.63-0.68; P < 0.001), CSS (HR 0.56, 95% CI 0.53-0.60; P < 0.001), and SREs (HR 0.64, 95%CI 0.59-0.71; P < 0.001) when controlling for age, race, Charlson comorbidity index, prostate-specific antigen, and Gleason score.
CONCLUSION:
The use of statins in men on ADT for CaP is associated with improved CSS and OS. Statins are inexpensive, well-tolerated medications that offer a promising adjunct to ADT, but require further prospective studies.
Copyright © 2018. Published by Elsevier Inc.
KEYWORDS:
Gonadotropin-releasing hormone/analogs and derivatives; Hospitals; Hydroxymethylglutaryl-CoA reductase inhibitors; Prostatic neoplasms; Veterans
PMID: 30528885 DOI: 10.1016/j.urolonc.2018.11.017
Unfortunately, it is only an observational database study among veterans (a unique population). There are obvious selection biases and unmeasured variables.
Other observational studies suggest a negative impact:
onlinelibrary.wiley.com/doi...
karger.com/Article/Abstract...
clinical-genitourinary-canc...
Several observational studies suggest no effect:
ncbi.nlm.nih.gov/pmc/articl...
auajournals.org/doi/10.1016...
nature.com/articles/pcan201331
onlinelibrary.wiley.com/doi...
nature.com/articles/pcan201310
onlinelibrary.wiley.com/doi...
(and more)
Two randomization studies proved there is no effect of statins on incidence of prostate cancer:
M I C - K E Y ... is doing quite well while on Lupron/Zytiga thank you.
Good Luck, Good Health and Good Humor.
j-o-h-n Thursday 03/28/2019 5:00 PM EDT
Denosumab vs Celebrex and Zometa
Zometa and Celebrex
L-Arginine and Prostate Cancer
Unfiltered Coffee and Prostate Cancer
